11. Goldstein S, Kennedy HL, Hall C, Anderson
JL, Gheorghiade M, Gottlieb S, Jessup M,
Karlsberg
RP,
Friday G, Haskell
L.
Metopro–
lo1 CR/XL in patients with heart failure: A
pilot study examining the tolerability, safety,
and effect on left ventricular ejection fraction.
Am Heart J 1999; 138: 1158-1165.
12. Hara Y, Hamada M, Shigematsu Y, Suzuki M,
Kodarna K, Kuwahara T, Hashida H, Ikeda S,
Ohtsuka T, Hiasa G, Hiwada K Effect of beta–
blocker on left ventricular function and natri–
uretic peptides in patients with chronic heart
failure treated with angiotensin-converting
enzyme inhibitor. Jpn Circ J 2000; 64: 365-9.
13. Troughton RW, Frampton CM, Yandle TG,
Espiner EA, Nicholls MG, Richards AM.Tre–
atment of heart failure guided by plasma ami–
noterminal brain natriuretic peptide (N-BNP)
concentrations. Lancet 2000; 355: 1126-1130.
14. Sundsfjord JA, Thibault G, Lamehelle P, Can–
tin M. Identification and plasma concentra–
tion of the N terminal fragment of proatrial
natriuretic factor in man. J Clin Endocrinol
Metab 1988; 66: 605-610.
15. Hunt PJ, Yandle TG, Nicholls MG, Richards
AM, Espiner EA.The amino-terminal portion
of pro-brain natriuretic peptide (Pro-BNP)
circulates in human plasma. Biochem Biop–
hys Res Commun 1995; 214(3): 1175-83.
16. Hall C, Aaberge L, Stokke O.
In
vitro stability
of N-terminal proatrial natriuretic factor in
unfrozen samples: an important prerequisite
for its use as a biochemical parameter of atrial
pressure in clinical routine. Circulation 1995;
91:911.
Klinisk Kjemi
i
Norden l , 2001
17. Wijbenga JAM, Balk AHMM, Boomsrna F,
Man in 't Veld AJ, Hall C. Cardiac peptides
differ in their response to exercise. Implicati–
ons for patients with heart failure in clinical
practice. Eur Heart J 1999; 20: 1424-1428.
18. Richards AM. Nicholls MG. Yandle TG.
Frampton C. Espiner EA. Turner JG. Butti–
more RC. Lainchbury JG. Elliott JM. Ikram
H. Crozier IG. Smyth DW. Plasma N-terminal
pro-brain natriuretic peptide and adrenome–
dullin: new neurohormonal predietors of left
ventricular function and prognosis after myo–
cardial
infarction.
Circulation
1998;
97:1921-1929.
19. Mukoyama M, Nakao K, Hosoda K, Suga S,
Saito Y, Ogawa Y, Shirakami G, Jougasaki M,
Obata K, Yasue H, et al. Brain natriuretic pep–
tide as a novel cardiac hormone in humans.
Evidence for an exquisite dual natriuretic pep–
tide system, atrial natriuretic peptide and
brain natriuretic peptide. J Clin lnvest 1991;
87(4): 1402-1412.
20. Struthers
AD.
N-terminal proBNP - the most
cost effective way to identify post myocardial
infarction left ventriular dysfunction? Eur
Heart J 2000; 21: 1490-1492.
13
